Synlogic Announces First Quarter 2022 Conference Call and Webcast
Synlogic, Inc. (Nasdaq: SYBX) announced it will release its Q1 2022 financial results on May 12, 2022, before market opening. Following the release, a conference call is scheduled at 8:30 am ET to discuss the results and business updates. Investors can join via telephone or webcast. Synlogic focuses on developing medicines for metabolic and immunological diseases using synthetic biology, with promising drugs in its pipeline targeting conditions like phenylketonuria and inflammatory bowel disease.
- Plans to start a pivotal Phase 3 study for the lead program in phenylketonuria in H2 2022.
- Strategic collaborations with Roche and Ginkgo Bioworks to enhance drug development capabilities.
- None.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its first quarter 2022 financial results before the market opens on Thursday, May 12, 2022. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 5149412. Participants may access the live webcast in the “Events Calendar” of the Investors & Media section of the website. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company's website.
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic’s approach to Synthetic Biotics with Ginkgo’s Codebase and Foundry services. For additional information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
SOURCE Synlogic, Inc.
Media Contact:
Bill Berry
Berry & Company Public Relations
212-253-8881; bberry@berrypr.com
Investor Contact:
Andrew Funderburk
Kendall Investor Relations
617-914-0008; afunderburk@kendallir.com
FAQ
What are the upcoming financial results for Synlogic (SYBX)?
When is the conference call for Synlogic's financial results?
What is Synlogic's lead program targeting?
Are there any new clinical trials for Synlogic (SYBX)?
